Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.84 |
| ▸ | MMP8 | P22894 | 13/20 | 0.84 |
| ▸ | MMP9 | P14780 | 13/20 | 0.84 |
| ▸ | MMP1 | P03956 | 7/20 | 0.80 |
| ▸ | MMP14 | P50281 | 2/20 | 0.66 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.66 |
| ▸ | ADAM12 | O43184 | 1/20 | 0.66 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.66 |
| ▸ | MMP3 | P08254 | 1/20 | 0.66 |
| ▸ | MMP7 | P09237 | 1/20 | 0.66 |
| ▸ | MMP12 | P39900 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.66 |
| ▸ | MMP15 | P51511 | 1/20 | 0.66 |
| ▸ | MMP16 | P51512 | 1/20 | 0.66 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.66 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.66 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.66 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.66 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458410 | 1.00 | MMP2 (0.84) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL6577793 | 0.89 | MMP2 (1.00) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL4795667 | 0.89 | MMP2 (0.85) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL6575025 | 0.89 | MMP2 (0.85) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL6575485 | 0.87 | MMP1 (0.82) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL7412775 | 0.86 | MMP2 (0.84) | MMP2MMP8MMP9MMP1MMP14 | |
| SCHEMBL8201153 | 0.85 | MMP9 (0.80) | MMP2MMP8MMP9MMP1MMP3 | |
| SCHEMBL8201151 | 0.85 | MMP9 (0.80) | MMP2MMP8MMP9MMP1MMP3 | |
| SCHEMBL8850370 | 0.85 | MMP9 (0.80) | MMP2MMP8MMP9MMP1MMP3 | |
| SCHEMBL7457278 | 0.84 | MMP1 (0.78) | MMP2MMP8MMP9MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5892112-A | ACYLATION OF AMINO ACIDS WITH ANHYDRIDES OR CARBOXY GROUPS, AMIDATION WITH AMINE AND CONVERSION OF ACID OR ESTER TO HYDROXAMIC ACID AND HYDROLYSIS | GLYCOMED INCORPORATED (US) | 1999-04-06 | — | — | US | claimed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| WO-2010062628-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GJB2, GPR180 | MMP2 3607/4885MMP8 1204/4885MMP9 2331/4885 |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP2 2528/4885MMP8 793/4885MMP9 2566/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP2 2983/4885MMP8 1039/4885MMP9 3488/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | MMP2 55/4885MMP8 9/4885MMP9 121/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | MMP2 338/4885MMP8 40/4885MMP9 328/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP2 11/4885MMP8 19/4885MMP9 1/4885 |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | RGS17, RGS16, CHRM3 | MMP2 2273/4885MMP8 626/4885MMP9 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.